Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cellectar Biosciences

4.80
+0.07001.48%
Post-market: 4.880.0800+1.67%16:56 EDT
Volume:238.95K
Turnover:1.18M
Market Cap:8.70M
PE:-0.21
High:5.17
Open:5.17
Low:4.61
Close:4.73
Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
13 May

Cellectar Biosciences Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
09 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 May

Cellectar BioSciences Inc. Unveils New Presentation on Phospholipid Drug Conjugates and Promising Advances in Oncology Treatments

Reuters
·
07 May

BRIEF-Cellectar Announces Plan To Explore Strategic Alternatives

Reuters
·
30 Apr

Cellectar Biosciences: Alternatives Include Identifying Strategic Partner With Resources to Develop Iopofosine I 131

THOMSON REUTERS
·
30 Apr

Cellectar Announces Plan to Explore Strategic Alternatives

THOMSON REUTERS
·
30 Apr

Cellectar Announces Plan to Explore Strategic Alternatives

GlobeNewswire
·
30 Apr

4 Medical Product Stocks to Buy From a Challenging Industry

Zacks
·
17 Apr

Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year?

Zacks
·
18 Mar

Cellectar Biosciences Enhances CEO and COO Severance Benefits

TIPRANKS
·
18 Mar

Cellectar Biosciences: Promising Future with FDA Clarity and Innovative Radiopharmaceutical Advancements

TIPRANKS
·
15 Mar

Oppenheimer Keeps Their Hold Rating on Cellectar Biosciences (CLRB)

TIPRANKS
·
14 Mar

Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ...

GuruFocus.com
·
14 Mar

Cellectar Biosciences Faces Financial and Legal Turmoil Amidst Restated Earnings

TIPRANKS
·
14 Mar

Cellectar Biosciences Advances Cancer Drug Pipeline

TIPRANKS
·
14 Mar

Q4 2024 Cellectar Biosciences Inc Earnings Call

Thomson Reuters StreetEvents
·
14 Mar

Cellectar Biosciences Earnings Call: Mixed Outlook Amid Successes and Challenges

TIPRANKS
·
14 Mar

Cellectar Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
13 Mar

Cellectar Biosciences reports FY24 EPS ($1.40), consensus ($1.57)

TIPRANKS
·
13 Mar